Antibiotic resistant Streptococcus pneumoniae

E J Minton, J T Macfarlane*
Department of Infectious Diseases and *Department of Respiratory Medicine, Nottingham City Hospital, Nottingham, UK

Introductory article

Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain

R Pallares, J Linares, M Vadillo, C Caballero, F Manresa, P F Viladrich, R Martin, F Gudiol

Background. Penicillin-resistant strains of Streptococcus pneumoniae are now found worldwide, and strains with resistance to cephalosporin are being reported. The appropriate antibiotic for pneumococcal pneumonia due to resistant strains remains controversial. Methods. To examine the effect of resistance to penicillin and cephalosporin on mortality, we conducted a 10-year, prospective study in Barcelona of 504 adults with culture-proved pneumococcal pneumonia. Results. Among the 504 patients, 145 (29 percent) had penicillin-resistant strains of S. pneumoniae (minimal inhibitory concentration [MIC] of penicillin G, 0.12 to 4.0 µg per milliliter), and 31 patients (6 percent) had cephalosporin-resistant strains (MIC of ceftriaxone or cefotaxime, 1.0 to 4.0 µg per milliliter). Mortality was 38 percent in patients with penicillin-resistant strains, as compared with 24 percent in patients with penicillin-sensitive strains (P=0.001). However, after the exclusion of patients with polymicrobial pneumonia and adjustment for other predictors of mortality, the odds ratio for mortality in patients with penicillin-resistant strains was 1.0 (95 percent confidence interval, 0.5 to 1.9; P=0.84). Among patients treated with penicillin G or ampicillin, the mortality was 25 percent in the 24 with penicillin-resistant strains and 19 percent in the 126 with penicillin-sensitive strains (P=0.51). Among patients treated with ceftriaxone or cefotaxime, the mortality was 22 percent in the 59 with penicillin-resistant strains and 25 percent in the 127 with penicillin-sensitive strains (P=0.64). The frequency of resistance to cephalosporin increased from 2 percent in 1984-1988 to 9 percent in 1989-1993 (P=0.002). Mortality was 26 percent in patients with cephalosporin-resistant S. pneumoniae and 28 percent in patients with susceptible organisms (P=0.89). Among patients treated with ceftriaxone or cefotaxime, mortality was 22 percent in the 18 with cephalosporin-resistant strains and 24 percent in the 168 with cephalosporin-sensitive organisms (P=0.64). Conclusions. Current levels of resistance to penicillin and cephalosporin by S. pneumoniae are not associated with increased mortality in patients with pneumococcal pneumonia. Hence, these antibiotics remain the therapy of choice for this disease. (N Engl J Med 1995;333:474-80)

For many years penicillin provided very effective treatment for pneumococcal infections. However, the last two decades have seen the emergence of pneumococcal strains with resistance not only to penicillin, but also to other antibiotics.1 This has contributed to treatment failure, at least in pneumococcal meningitis.2 In spite of this, it has been suggested that penicillin may still be an effective treatment for pneumococcal pneumonia as very high tissue concentrations of antibiotic can be achieved.3 In August 1995 Pallares and colleagues, working in Barcelona where the incidence of penicillin resistance in pneumococci is particularly high, published a study comparing mortality from pneumonia due to penicillin sensitive pneumococci with that due to penicillin resistant strains.4 Their results suggest that there may be little difference in mortality between the two groups after correction for an increased incidence of poor prognostic factors amongst those patients with resistant infections.

In this review we will provide a general introduction to the topic of antibiotic resistant pneumococci, discuss the paper by Pallares et al in more detail, and finally make our own suggestions on how to deal with the difficult clinical problem of increasing antibiotic resistance in pneumococci.

Pneumococcal infection and the development of antibiotic resistance

PNEUMOCOCCAL PNEUMONIA: THE SIZE OF THE PROBLEM

Pneumococcal infection remains the commonest cause
of community acquired pneumonia in the UK (76% of adult hospital admissions for community acquired pneumonia in Nottingham in 1982)\(^2\). In the USA there are approximately half a million episodes of pneumococcal pneumonia each year with 40 000 deaths.\(^3-7\) In developing countries over a million children under the age of five years die annually from pneumonia, most commonly due to *Streptococcus pneumoniae*.\(^8\) Pneumonia due to pneumococci is commoner in the elderly,\(^9\) in those with underlying disease particularly immunosuppression such as haemophiliac and HIV disease,\(^10,11\) and in alcoholics and vagrants.\(^12\) There is a marked seasonal variation with peak incidence in the winter months.\(^12,13\)

**PATHOGENESIS OF PNEUMOCOCCAL PNEUMONIA**

*Streptococcus pneumoniae* is found as normal nasopharyngeal and oropharyngeal flora in approximately 15% of children and 5% of adults.\(^14\) It is thought to be passed from person to person via respiratory secretions and aerosols. Impairment of host defence mechanisms within the bronchial tree such as ciliary movement, cough and secretory immunoglobulin (for example, in chronic lung disease or an acute viral infection) may allow pneumococci to gain access to the lower respiratory tract. The organisms are surrounded by a capsule composed of polysaccharide antigen (used in strain typing) which inhibits phagocytosis. Antibodies to the polysaccharide capsule are protective, suggesting that this is an important virulence factor. Other virulence factors include pneumolysin O, a toxin which causes cell lysis, and a neuraminidase which degrades host cell surface structures. Components of the pneumococcal cell wall are able to interact with C-reactive protein resulting in the activation of host non-specific immune responses.\(^14\)

**DEVELOPMENT OF TREATMENT FOR PNEUMOCOCCAL INFECTION**

At the beginning of this century the mortality from pneumococcal pneumonia approached 75%.\(^15\) Initial treatment was optochin, a drug related to quinine which, although effective, had to be abandoned for clinical use because of ocular toxicity.\(^16\) (It is still used for the identification of pneumococci in the laboratory today.) Pneumococcal antisera and sulphonamides both improved the survival from pneumococcal disease, but the introduction of penicillin reduced the overall mortality rate to approximately 25%,\(^17\) which has remained constant for many years in spite of development of intensive care techniques including positive pressure ventilation.\(^18\)

**APPEARANCE OF PENICILLIN RESISTANT PNEUMOCOCCI**

Not long after the introduction of penicillin in 1940 the first penicillin resistant pneumococcus was produced in vitro,\(^19\) but the first clinical isolate did not appear until 20 years later in Boston, USA.\(^20\) In the late 1960s a number of penicillin resistant strains were isolated in Australia and New Guinea, possibly related to a trial of prophylactic oral penicillin in an attempt to reduce the incidence of pneumococcal disease.\(^21,22\) In the 1970s an epidemic of penicillin and later multidrug resistant pneumococci was seen in paediatric wards in South Africa and in Europe, particularly Spain and Hungary (fig 1).\(^1,12-25\)

**DIAGNOSIS AND DEFINITION OF PENICILLIN RESISTANT PNEUMOCOCCAL INFECTION**

Pneumococci may be identified by Gram staining of specimens such as respiratory secretions, followed by conventional culture techniques, looking for characteristic colonial morphology, α-haemolysis and optochin sensitivity, plus specific reactions with antisera to capsular polysaccharides.\(^14\) Penicillin sensitivity is screened for by disc diffusion techniques. Filter paper discs containing a standardised amount of antibiotic are applied to an agar plate inoculated with the bacterial isolate. After incubation a zone of growth inhibition is present around the disc if the isolate is sensitive to the antibiotic. More sensitive isolates have larger inhibition zones which may be quantified approximately by comparison with a previously characterised strain. In order to quantify accurately the minimum inhibitory concentration of antibiotic (MIC) for a particular isolate, more time consuming microdilution techniques are necessary. A pneumococcal isolate is considered to be sensitive to penicillin if the MIC is <0.6 μg/ml. An isolate with intermediate resistance has an MIC of 0.6-1 μg/ml, while the term “high level resistance” is used to describe isolates with MICs of ≥2 μg/ml. The E-test, a strip of paper impregnated with increasing concentrations of an antibiotic, is a newer less laborious method based on antibiotic diffusion techniques which allows an approximate estimate of the MIC.\(^26\)

**MECHANISMS OF ANTIBIOTIC RESISTANCE**

Penicillins work by binding to a number of proteins (usually enzymes) essential for the synthesis of the bacterial cell wall and inhibiting their function. Penicillin resistant pneumococci have been shown to have penicillin binding proteins (PBP) with much reduced affinity for penicillin, so that the presence of penicillin does not interfere with bacterial wall synthesis (fig 2).\(^27\) There are thought to be at least two mechanisms whereby low affinity PBPs are acquired by pneumococci. Other bacteria, particularly viridans streptococci, may transfer genetic material encoding low affinity PBP genes to pneumococci.\(^28\) Both types of bacteria may be carried in the oropharynx so that they may come into close proximity. In addition, the presence of penicillin exerts a selective pressure on pneumococci favouring point mutations causing a reduction in PBP affinity and thus an increase in MIC.\(^29\) Cephalosporin resistance is also mediated by changes in PBP affinity, but fewer genetic changes are required for resistance to occur.\(^30\) The genes for antibiotic resistance may be spread amongst different pneumococcal clones or serotypes by exchange of genetic information.\(^31\) In addition, a resistant strain can be spread geographically by colonisation of new hosts, as
been in from patients rather than increases prophylactic to reduce the observation mococci. Some Streptococcus more penicillin reaches in low overall incidence of antibiotics disease, socioeconomic status may predispose to pneumococcal infection, access to medical care and prior exposure to antibiotics may be a more important predisposing factor for infection with antibiotic resistant pneumococci. The number of patients with high level penicillin resistant isolates also increased from 6% to 15%. Cephalosporin resistance was usually found in association with resistance to penicillin. No vancomycin resistance was seen.

**Mortality**

Overall mortality was significantly greater for those patients infected with penicillin resistant pneumococcal strains (38%) than penicillin susceptible strains (24%). However, multivariate analysis revealed a number of independent predictors of poor prognosis including age >70, shock, and multisystem, nosocomial and polymicrobial infections. These factors occurred with greater frequency in the group of patients infected with penicillin.
resistant pneumococci. Once such poor prognostic factors were taken into account there was no significant difference in mortality between the penicillin resistant and penicillin susceptible groups. Thus, the isolation of penicillin resistant pneumococci from a patient may be a marker for poor prognosis, as has been observed for vancomycin resistant enterococci. A No difference in severity of infection at presentation was found between the two groups, which suggests that the presence of penicillin resistance has no effect on pneumococcal virulence. No difference in mortality (uncorrected) was found between patients infected with cephalosporin sensitive in comparison to cephalosporin resistant strains. The patients who were HIV positive had a lower overall mortality, perhaps because these patients were younger than the study group as a whole.

RESPONSE TO ANTIBIOTIC THERAPY
This study was not carried out as a randomised controlled trial, so only limited conclusions can be drawn about the effectiveness of different antibiotic strategies. In addition, the antibiotic treatment of patients was reviewed and sometimes changed in the light of culture results, but this has not been taken into account in the data analysis. In such cases it is not clear whether the data were analysed with regard to initial or final choice of antibiotic. With these caveats, there was no significant difference in mortality rates for patients treated with penicillin or ampicillin regardless of whether they were infected with a penicillin sensitive or resistant pneumococcal strain. This was so for both overall mortality rates, and mortality rates adjusted for the presence of poor prognostic factors. Likewise, penicillin resistance did not appear to have any effect on the outcome of patients treated with ceftriaxone or cefotaxime, or with other antibiotic regimes. The authors point out that eight of nine patients receiving penicillin for isolates with MICs of $\geq 2 \mu g/ml$ (high level resistance) recovered. In addition, of eight patients who received cephalospors for high level penicillin resistant isolates all but one patient survived. However, the numbers of patients with high level penicillin resistance were small so that treatment failures here might not be apparent.

For those patients with cephalosporin resistance the number of patients (n=5) treated with cephalosporin was too small to judge whether cephalospors are effective despite the presence of resistance. Nonetheless, there was little difference in overall mortality for cephalosporin resistant isolates regardless of the antibiotic treatment regimen used.

Approaches to the management of pneumococcal antibiotic resistance

TREATMENT OF ANTIBIOTIC RESISTANT STREPTOCOCCUS PNEUMONIAE
Apart from the study by Pallares and colleagues, there is other evidence that $\beta$-lactam antibiotics are effective against pneumococci with intermediate penicillin resistance. A study of South African children with pneumococcal pneumonia showed no significant difference in mortality between those with fully sensitive pneumococcal strains (11%) and those with intermediate resistant strains (14%) when both received $\beta$-lactam antibiotics.58 Studies in Spain and in Houston similarly failed to show any difference in outcome.32 Thus, as suggested by Pallares et al, high dose penicillin remains the treatment of choice for pneumococcal pneumonia, provided the MIC of the isolate is $\leq 1 \mu g/ml$. In patients from whom pneumococci with high level resistance have been isolated, failure of penicillin has been documented, particularly in subjects with underlying disease.33 In this situation high dose third generation cephalosporins, vancomycin or imipinem may be used, perhaps in combination with an aminoglycoside to provide synergy.35 Empirical therapy, according to Pallares and colleagues, should be based on the assessment of risk factors for infection with a penicillin resistant pneumococcus — for example, local incidence of penicillin resistance or likelihood of nosocomial infection (table 1). If no risk factors are present, and the probability of death appears low, then these patients can be treated with conventional regimens (benzyl penicillin, ampicillin or amoxicillin). However, if the patient is severely ill or has risk factors of penicillin resistance, they recommend the use of ceftriaxone or cefotaxime with erythromycin if an atypical pathogen cannot be ruled out. If high level cephalosporin resistance is present locally, then alternative regimens such as vancomycin or imipenem should be considered.41 For pneumococcal disease at other sites, particularly meningitis, it may not be possible to achieve sufficient local penicillin concentrations to treat pneumococci with intermediate resistance with penicillin. Treatment with a third generation cephalosporin such as ceftriaxone or cefotaxime may be necessary in this situation. In areas where cephalosporin resistant pneumococci are present, combination therapy with cefotaxime/ceftriaxone and vancomycin has been recommended.41

In the UK and other countries where the prevalence of antibiotic resistant pneumococci is low there is no reason to change the standard treatment for pneumococcal pneumonia at present, although it may be prudent to err on giving higher rather than lower doses of penicillin or amoxycillin to cover possible intermediate resistant strains. However, it is essential to continue careful surveillance of pneumococcal resistance throughout the country in order to detect an increase in prevalence which might necessitate a change in policy. Pneumococcal meningitis should be treated with large doses of cefotaxime (2 g every six hours) or ceftriaxone (4 g per day) until sensitivities are available (table 2).

| Table 1 Risk factors for infection with penicillin resistant Streptococcus pneumoniae |
|---------------------------------------------------------------|
| High local prevalence of penicillin resistant pneumococci |
| Exposure to $\beta$-lactam antibiotics within previous 3 months |
| Admission to hospital within previous 3 months |
| Underlying immunsuppressive disease |
| Episodes of pneumonia within the previous year |
| Initial critical condition* |

* Defined as two or more of the following: (1) severe underlying disease, (2) age of 75 or more, (3) leukopenia, (4) shock, (5) multiorgan involvement.

VACCINES
Because of the many different pneumococcal serotypes it is not possible to protect against all pneumococcal infections with a single vaccine. This problem was partially solved by the development of polyvalent vaccines containing initially 14 and, since 1984, 23 different pneumococcal serotypes (Pneumovax II).42 The serotypes contained in the latter preparation cover 80–90% of episodes of pneumococcal infection in most countries. The vaccine also includes most of the serotypes in which pneumococcal resistance is most commonly seen.44 Pneumovax is recommended for individuals with im-
munodeficiency states including hyposplenism and HIV infection; chronic lung, cardiac, hepatic and renal disease; and diabetes mellitus. In the USA it is also recommended for all individuals over the age of 65.44 The overall efficacy varies according to the patient group vaccinated and is estimated to be 56% overall, reaching 75% in the immunocompetent population.44 It appears to be less effective in patients with chronic renal failure and haematological malignancies. Uptake of the vaccine, at least in the USA, has been a problem with only 28% of the target population receiving it even after an awareness campaign.45 Unfortunately the vaccine is not effective in children under two years of age because of immaturity of the immune system. In addition, the capsular polysaccharide antigens do not induce high level, high affinity antibodies or T cell memory as do the peptide-based or protein-based antigens. Thus, new conjugate vaccines are being developed using protein carriers attached to capsular polysaccharide in the hope of improving protection, as has been achieved for the Hib conjugate vaccine. The diversity of the pneumococcal polysaccharides makes this a much more complex task, and initial conjugate vaccines are likely to include only the seven most common serotypes.46 We consider the use and development of pneumococcal vaccines as an important means of prevention of resistant pneumococcal disease in at risk groups.

ANTIBIOTIC USAGE

As described above, the occurrence of antibiotic resistant Streptococcus pneumoniae is frequently related to antibiotic usage. Antibiotic prescribing has been shown to be inappropriate in many instances – for example, viral infections where no effect has been shown on either symptom duration or secondary bacterial infection.47 As many as 50% of outpatient antibiotic prescriptions were considered unnecessary in one US study.48 In the UK antibiotic prescription rates have increased by nearly 50% between 1980 and 1993.49 Although the reasons for this increase in antibiotic prescribing have not yet been investigated, it has been suggested that this is due to a gradual increase in the use of antibiotics for respiratory symptoms. In one recent study of 1089 adults who presented to their general practitioner with acute lower respiratory symptoms, three quarters received an antibiotic even though the GP felt antibiotics to be definitely indicated in less than a third of treated cases and not needed in a fifth. Factors such as patient pressure and GP work pressure were found to contribute to the prescribing of unnecessary antibiotics.50 In some countries antibiotics can be obtained without prescription which may lead to inappropriate use and the development of resistance. The use of antibiotics in animal food stuffs and in veterinary practice is not well regulated in many countries and may lead to the emergence of resistance genes which may be passed from animal microbial flora to human pathogens.51 More careful regulation of antibiotic use is necessary to limit the development, not only of antibiotic resistant pneumococci, but other resistant bacteria such as methicillin resistant Staphylococcus aureus and vancomycin resistant enterococci. Enterococci are fairly closely related to streptococci and thus the potential exists for transfer of genetic material encoding vancomycin resistance from enterococci to pneumococci. Such an event would leave very few antibiotics effective against pneumococci.

LEARNING POINTS

• The incidence of penicillin and cephalosporin resistant pneumococci is increasing.

• High dose penicillin is still effective in intermediate resistant pneumococcal bacteraemia and pneumonia, but probably not in meningitis.

• Alternative antibiotic regimens are required for pneumococci with high level penicillin resistance; surveillance of local antibiotic resistance is critical for selection of appropriate empirical therapy.

• Pneumococcal vaccines protect against most pneumococcal serotypes with antibiotic resistance and should be given more frequently, especially in areas where antibiotic resistant pneumococci are common.

• Antibiotic usage should be more carefully regulated to limit the emergence of antibiotic resistant bacteria.
Conclusion

There is evidence from many different centres throughout the world that the incidence of resistance in pneumococci, not only to penicillin but also to other antibiotics, is increasing rapidly. The evidence presented by Pallares and colleagues is somewhat reassuring in that, for the moment, many of these pneumococcal strains show only intermediate penicillin resistance and, at least in pneumonia, respond to high dose penicillin. However, high level resistance to penicillin and also to cephalosporins is becoming more common, and such strains may require alternative antibiotic regimes. Other strategies which may help to prevent disease due to resistant pneumococci include the increased use of existing pneumococcal vaccines and the development of improved conjugate vaccines. The problem of inappropriate antibiotic use needs to be urgently addressed to control the development, not only of antibiotic-resistant Streptococcus pneumoniae, but also many other species of resistant bacteria.

1. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992;15:77–83.
2. Watterson TK, Cappuccio FA. Meninings due to penicillin-resistant Streptococcus pneumoniae in adults. Rev Infect Dis 1990;12:1166–74.
3. Pallares R, Gudiol F, Linares J, Ariza R, Fuji G, Murgui L, et al. Risk factors and response to antibiotic therapy in adults with pneumococcal pneumonia due to penicillin-resistant pneumococci. N Engl J Med 1987;317:18–22.
4. Pallares R, Linares J, Vidalillo M, Cabelles C, Manresa F, Viladrich PF, et al. Resistance to the fluoroquinolones and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474–80.
5. Macfarlane GR, Breast JD, Finch RG, Macae AE. Hospital study of adult community-acquired pneumonia. Lancet 1982;ii:295–6.
6. CDC. Pneumococcal vaccine usage. United States. MMWR 1984;33:273–6.
7. Williams WW, Hickson MA, Kane MA, Kendall AP, Spika JS, Hinman AR. Immunization policies and vaccine coverage among adults: the risk for missed opportunities. Ann Intern Med 1986;105:618–25.
8. Berman M, Grinsell M. Initial community health centres: strategies for control of disease in the developing world. XXI. Acute respiratory infections. Rev Infect Dis 1985;7:674–9.
9. Finkelstein MS, Petkan WM, Freedman ML, Antopol SC. Pneumococcal bacteremia in adults: age-dependent differences in presentation and in outcome. J Am Geriatr Soc 1983;31:19–27.
10. Garcia-Leone ME, Moreno S, Rodero P, Carcedo E, Vincente T, Bouza E. Pneumococcal pneumonia in adult hospitalized patients infected with the human immunodeficiency virus. Arch Intern Med 1996;156:1729–37.
11. Jarrot EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection. Ann Intern Med 1992;117:314–21.
12. Granado-Ferreira M, Voller SI, Phillips J. Pneumococcal bacteremia in adults: age-depending differences in presentation and in outcome. J Am Geriatr Soc 1983;31:19–27.
13. Mootis JM, Beam TR. Comparison of community-acquired and nosocomial pneumococcal bacteremia. Am Rev Respir Dis 1981;123:265–8.
14. Baran EJ, Peterson LR, Finegold SM. Streptococci and related genera. In: Eaton DJ, & Scan J Diagnost Microbiol. St Louis: Mosby 1987: 348–49.
15. Tilghman RC, Finland M. Clinical significance of bacteremia in pneumococcal pneumonia. Arch Intern Med 1973;130:602–19.
16. Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1994;121:807–8.
17. Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1994;121:807–8.
18. Hoff EW, Horton CA, Schaberg DR. Failure of intensive care unit support to influence mortality from pneumococcal pneumonia. JAMA 1992;268:1055–7.
19. Schmidt LH, Sesler CL. Development of resistance to penicillin by pneumococci. Proc Soc Exp Biol Med 1953;82:535–7.
20. Klasa PJ, van Bijnen JS, Phillips BM. Susceptibility of pneumococci to nine antibiotics. Am J Med Sci 1965:261–8.
21. Hansten D, Bullen M. A resistant pneumococcus. Lancet 1967:264–5.
22. Hansman D, Goh B, Devitt HS, Hortnig E, Shulman L, et al. Antimicrobial resistance of Streptococcus pneumoniae in India. J Infect Dis 1987;155:757–64.
23. Koomkho H, Wasse A, Klueman K. Antimicrobial resistance in Streptococcus pneumoniae: A South African perspective. Clin Infect Dis 1992;15:84–94.
24. Linares J, Pallares R, Alonso T, Perez JL, Ayats J, Gudiol F, et al. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979–1990). Clin Infect Dis 1992;15:99–105.